SCHEMBL10314593

SCHEMBL10314593

COc1ccc(Cn2c(=O)c3c(OC)c(C=O)n(C)c3c3ccccc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX4 Q99571 1/20 0.54
▸ ALDH1A1 P00352 5/20 0.49
▸ BLM P54132 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ LMNA P02545 4/20 0.47
▸ POLB P06746 3/20 0.47
▸ TDP1 Q9NUW8 3/20 0.47
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ GAA P10253 3/20 0.46
▸ RECQL P46063 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ MAPK1 P28482 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ CTDSP1 Q9GZU7 1/20 0.45
▸ MAPT P10636 5/20 0.45
▸ GABRA5 P31644 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10314592 0.89 P2RX4 (0.53) P2RX4ALDH1A1BLMSMN1; SMN2LMNA
SCHEMBL1058142 0.83 P2RX4 (0.54) P2RX4ALDH1A1BLMSMN1; SMN2LMNA
SCHEMBL1061698 0.79 KMT2A (0.50) P2RX4ALDH1A1BLMSMN1; SMN2LMNA
SCHEMBL10314604 0.78 SMN1; SMN2 (0.50) ALDH1A1BLMSMN1; SMN2LMNAPOLB
SCHEMBL12962916 0.74 P2RX4 (0.62) P2RX4ALDH1A1BLMSMN1; SMN2LMNA
SCHEMBL1062493 0.73 FEN1 (0.51) P2RX4ALDH1A1BLMSMN1; SMN2LMNA
SCHEMBL10314502 0.73 HDAC1 (0.44) P2RX4ALDH1A1BLMSMN1; SMN2POLB
Hydrochloric Acid SCHEMBL1061359 0.73 HDAC1 (0.43) P2RX4ALDH1A1BLMSMN1; SMN2POLB
SCHEMBL10314548 0.72 P2RX4 (0.53) P2RX4ALDH1A1BLMSMN1; SMN2LMNA
SCHEMBL14160793 0.71 P2RX4 (1.00) P2RX4ALDH1A1BLMSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 P2RX4 2153/4885ALDH1A1 745/4885BLM 3886/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 P2RX4 2459/4885ALDH1A1 776/4885BLM 3924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback